News
Ending cancer service delays and backlogs: voices from the frontline
Pandemic-related delays and backlogs in cancer diagnosis, screening and treatments can be rapidly addressed if health services invest now in data systems that monitor needs and resources, together with innovative ways to meet that need. This was the key message…
Study provides insights into long-term effects of childhood cancers
People surviving childhood cancers have a higher risk of other morbidities as they grow older. The study, published online The Lancet Regional Health-Europe (14 November), found that a greater burden of disease was experienced by patients receiving combined treatment with…
Study challenges dogma that RCC is biologically radioresistant
Stereotactic body radiation therapy (SBRT) represents a safe and effective non-invasive treatment for oligometastatic renal cell carcinoma (RCC). The study, published in Lancet Oncology, supports sequential radiotherapy as an alternative treatment option to systemic therapy for oligometastatic renal cell carcinoma.…
Systematic review fills knowledge gaps about metastatic breast cancer
In breast cancer the risk of metastasis is higher among women diagnosed at a younger age, those with larger tumours at diagnosis and those with luminal B breast cancer. The study, abstract 0R-91, presented at the Advanced Breast Cancer Sixth International…
Atlas provides ‘one-stop shop’ for myeloma care information across Europe
Myeloma Patients Europe (MPE) has launched an overview of myeloma and AL amyloidosis treatment inequalities across Europe. The Myeloma Access Atlas, released 19 October, is a platform which has been developed to provide a ‘one-stop’ shop mapping national availability of…
Most basic cancer drugs remain inaccessible in low- and lower-middle-income countries
Despite being available for more than 20 years, basic cancer drugs found to be most effective against the disease can still not be accessed by patients in most low- and lower-middle-income countries according to a new study. The paper, published…
What’s new in lung and colorectal cancer? reports from ESMO 2021
New research findings presented at ESMO 2021 show progress in adjuvant treatment for non-small-cell lung cancer (NSCLC), a novel inhibitor for HER2+ NSCLC patients, and the latest from the FOCUS 4 adaptive, molecularly stratified, umbrella trial platform, set up to…
Dexamethasone helps cancer patients with non-immunogenic tumours survive longer after surgery
Patients with non-immunogenic cancers, such as breast and gynaecological cancers, who are given the anti-nausea drug dexamethasone during surgery survive longer. The study, abstract 4224, presented at the Anesthesiology 2021 annual meeting, held October 8 to 12, San Diego, found…
What’s new in supportive care? presentations from ESMO 2021
Supportive care studies presented at ESMO Congress 2021 highlight the urgent need for survivors to get more support to tackle long-term symptoms and for doctors and patients to get up to date information in a fast-changing oncology landscape. The need…
Round-up of prostate and breast cancer studies from ESMO 2021
The 2021 Congress of the European Society for Medical Oncology (ESMO), held 16‒21 September, featured studies that are likely to impact a broad spectrum of clinical practice. We summarise some of the findings that could change treatments for two of…